Shrikant Akolkar's questions to Dr Reddy's Laboratories Ltd (RDY) leadership • Q4 2025
Question
Shrikant Akolkar inquired about the competitive landscape for generic semaglutide in Canada, noting four filers, and asked about Dr. Reddy's specific approval timeline.
Answer
CEO Erez Israeli stated that while he cannot predict which competitors will launch, Dr. Reddy's plans to be ready to launch on the date the market opens. He expects to receive approval sometime near the end of the current calendar year (2025).